Researchers have identified a metabolite in python blood that could lead to new weight loss therapies, potentially avoiding the adverse side effects of current drugs like Ozempic. The discovery stems from studying the extreme metabolic flexibility of pythons, which can survive prolonged fasting followed by massive feeding events.
The Python’s Metabolic Secret
Pythons exhibit remarkable physiological adaptations to their feast-or-famine lifestyle. After consuming large prey, their metabolism accelerates up to 40 times, their heart size can increase by over 24%, and their gut microbiome prepares for the rare but substantial intake of food. Scientists are now focusing on byproducts of this bacterial activity in the snakes’ blood.
pTOS: A Key Metabolite Identified
A study led by Leslie Leinwand of the University of Colorado Boulder and Jonathon Long of Stanford University analyzed blood samples from ball pythons and Burmese pythons after feeding. Among 208 metabolites that spiked significantly, para-tyramine-O-sulfate (pTOS) increased over 1,000-fold. This compound is produced by gut bacteria during the breakdown of the amino acid tyrosine.
Impact on Mammalian Metabolism
Although pTOS’s effects on humans remain largely unknown, preliminary tests on mice show promising results. Both obese and lean mice ate significantly less food after receiving high doses of pTOS, leading to weight loss without the typical gastrointestinal issues, muscle loss, or energy decline associated with other treatments.
Activation of Satiety Neurons
The study found that pTOS activates neurons in the ventromedial hypothalamus, a critical brain region regulating hunger, satiety, and energy balance. This suggests that pTOS mimics a natural signal to the brain indicating sufficient food intake, similar to how it functions in pythons.
Future Implications for Human Therapies
Leinwand believes this discovery could lead to appetite suppressants with fewer side effects than existing GLP-1 drugs. While further research is needed to translate these findings into human medicine, this study highlights the potential of studying extreme metabolic adaptations in nature to develop innovative treatments.
“We’ve basically discovered an appetite suppressant that works in mice without some of the side-effects that GLP-1 drugs have,” Leinwand stated.
This discovery underscores the importance of looking beyond conventional animal models, like mice and rats, to explore the metabolic extremes found in other species for potential breakthroughs in human health.
